[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Guangzhou University of Chinese Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":133},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,80,107],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100053988","comparison-of-three-airway-intubation-devices-for-first-attempt-success-in-general-anesthesia-patients-100053988",false,"NCT07699653","Comparison of Three Airway Intubation Devices for First-Attempt Success in General Anesthesia Patients","Application of SPHJ-II, Visual Lighted Stylet, and Visual Intubation Fiberscope in Endotracheal Intubation in Patients Under General Anesthesia","Inclusion Criteria:\n\n* Age 18 to 65 years, inclusive. American Society of Anesthesiologists (ASA) physical status I to III. Scheduled for surgery under general anesthesia requiring endotracheal intubation.\n\nThe participant or legally authorized representative is fully informed of the purpose, methods, potential risks, and possible benefits of the study and provides written informed consent.\n\nExclusion Criteria:\n\n* Anticipated severe difficulty with mask ventilation, such as severe obesity (BMI \\> 35 kg\u002Fm²) with obstructive sleep apnea syndrome, history of neck radiotherapy, craniofacial malformation, or other conditions judged by the attending anesthesiologist to confer high risk for mask ventilation, and patients requiring awake tracheal intubation.\n\nCervical spine instability, cervical trauma, rheumatoid arthritis involving the cervical spine, ankylosing spondylitis, or any condition requiring absolute cervical immobilization during the procedure.\n\nSignificant airway involvement identified preoperatively, including imaging evidence of tracheal narrowing with minimal diameter \\\u003C 5 mm, severe tracheal compression, displacement or collapse, stridor at rest or after activity, vocal cord paralysis with dyspnea, giant thyroid mass with orthopnea, or other oral, pharyngeal, or laryngeal tumor, edema, stenosis, abscess, or severe upper airway anatomical abnormality affecting glottic exposure or endotracheal tube passage.\n\nHigh risk of reflux and aspiration. Severe cardiovascular disease, severe respiratory disease, severe hepatic or renal dysfunction, severe coagulation disorder, frailty, pregnancy or breastfeeding, or known allergy.\n\nAny other condition making the patient unsuitable for participation in the study, such as psychiatric illness, communication disorder, or poor compliance.","ALL","18 Years","65 Years",{"count":20,"type":21},549,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to compare three airway intubation devices in adult patients undergoing general anesthesia who require tracheal intubation. The main questions it aims to answer are:\n\n* Does the SPHJ-II video-assisted adjustable red-light fluoroscopic tracheal intubation scope improve first-attempt intubation success compared with a visual lighted stylet and a visual intubation fiberscope?\n* How do the three devices compare in intubation efficiency, intubation-related complications, and peri-intubation physiological responses?\n\nResearchers will compare the SPHJ-II, the visual lighted stylet, and the visual intubation fiberscope to evaluate their performance during tracheal intubation.\n\nParticipants will be randomly assigned to one of the three device groups and undergo tracheal intubation during general anesthesia using the assigned device.",[27,28,29],"Airway Management","General Anesthesia","Tracheal Intubation",[31,32,33,34,35],"SPHI-II","Visual lighted stylet","Visual intubation fiberscope","First-attempt intubation success","Randomized controlled trial","NOT_YET_RECRUITING","2026-07-08",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":21},"2026-07",{"date":44,"type":21},"2026-12-31",{"name":46,"class":47},"Guangzhou University of Chinese Medicine","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100605354","fus-subcutaneous-needling-for-postacute-lateral-ankle-sprain-and-prevention-of-chronic-ankle-instability-100605354","NCT07161427","Fu's Subcutaneous Needling for Postacute Lateral Ankle Sprain and Prevention of Chronic Ankle Instability","Biomechanics-based Fu's Subcutaneous Needling Versus Bracing Combined With Resistance Training in the Treatment of Postacute Lateral Ankle Sprain and the Prevention of Chronic Ankle Instability: A Randomized Controlled Trial Protocol","Inclusion Criteria:\n\n1. Patients with first-time lateral ankle sprains\n2. The patient presents with symptoms of swelling and aching and weakness in the ankle joint. There may be a feeling of friction during joint movement, and the symptoms are aggravated after long - distance walking or on rainy and overcast days.\n3. The patient presents with swelling and tenderness in the anteroinferior aspect of the lateral malleolus and the anterolateral aspect of the medial malleolus, and has limited mobility during inversion and flexion-extension.\n4. Auxiliary examinations: No fracture or dislocation was found in the patient during the examination, and no fracture was detected by X-ray examination.\n5. The patient's sprain time is more than 3 weeks and within 6 months.\n6. Those who have not received surgical treatment at other medical institutions before coming to our hospital for treatment, can complete the treatment and accept follow - up.\n7. The patients' ages range from 18 to 60 years old.\n8. The patient voluntarily and is capable of signing the Informed Consent Form.\n\nExclusion Criteria:\n\n1. Those with complete rupture of fractures or soft tissues such as muscles, tendons, and ligaments\n2. Patients with severe primary diseases such as heart, liver, kidney, hematopoietic system diseases and mental diseases\n3. Patients with tumors or tuberculosis in the ankle joint\n4. Patients with rheumatic and rheumatoid arthritis, or gout.\n5. Patients with acute inflammatory reactions such as redness, swelling, heat and pain and signs of infection in the ankle joint, or those accompanied by severe osteoarthritis.\n6. Patients with abnormal coagulation function or bleeding tendency, such as those with thrombocytopenia and severe diabetes.\n7. Patients during pregnancy and lactation\n8. Patients with damaged skin at the necessary needle insertion sites.","60 Years",{"count":58,"type":21},62,[24],"Introduction: Fu's Subcutaneous Needling (FSN) is a new type of acupuncture treatment method based on the subcutaneous tissue sweeping technique, and it has been proven to have a good therapeutic effect on ankle sprain. However, at present, the difference between its curative effect and the ankle joint orthosis and exercise therapy recommended by the Guidelines remains unclear. Therefore, this study aims to explore the improvement effects of FSN on pain relief, joint function improvement, and ankle balance ability by comparing with ankle orthosis combined with exercise therapy. Verify whether it is more helpful in preventing the progression of lateral ankle sprain (LAS) to chronic ankle instability (CAI) and provide evidence-based basis for clinical decision-making.\n\nMethods and analysis: This study is a randomized, parallel - controlled, single - center prospective clinical study. This study will include 60 subjects with postacute lateral ankle sprain and divide them into the FSN group and the combined treatment group. There are 30 cases in each group. The FSN group will be treated with Fu's subcutaneous needling three times a week for a total of two weeks. The Combined treatment group will wear ankle orthotics from 9:00 to 20:00, and complete resistance exercise training every day for a total of two weeks.Patients will be followed up for 6 months after the treatment. The main efficacy index is the change value of the Visual Analog Scale (VAS) compared to the baseline after 2 weeks of treatment. The secondary indicators include active range of motion (ROM) of the ankle joint, Star Excursion Balance Test (SEBT), and the Foot and Ankle Ability Measure (FAAM) to prove the clinical efficacy.\n\nEthics and dissemination: This study strictly adheres to the ethical guidelines of the Declaration of Helsinki.This study has passed the review of the Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine. Approval No.: YF 2025 - 158 - 01. All subjects will sign a written informed consent form. The research results will be publicly published in journals indexed by SCI.\n\nKeywords: Fu's subcutaneous needling, Ankle sprain, Postacute lateral ankle sprain, Chronic ankle instability, Functional rehabilitation, Balance, Non-surgical therapy",[62,63],"Chronic Ankle Instability","Lateral Ankle Sprain",[65,66,67,68,69,70,71],"Fu's subcutaneous needling","Ankle sprain","Postacute lateral ankle sprain","Chronic ankle instability","Functional rehabilitation","Balance","Non-surgical therapy","2025-09-14",{"date":74,"type":40},"2025-09-16",{"date":76,"type":21},"2025-10-01",{"date":78,"type":21},"2027-09-01",{"name":46,"class":47},{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":48},"100597128","clinical-study-on-the-healing-of-distal-radius-fractures-with-conservative-treatment-assisted-by-fus-subcutaneous-needling-100597128","NCT07054463","Clinical Study on the Healing of Distal Radius Fractures With Conservative Treatment Assisted by Fu's Subcutaneous Needling","Fu's Subcutaneous Needling-assisted Conservative Treatment for Distal Radius Fracture Healing: Protocol for a Randomized Controlled Trial","Inclusion Criteria:\n\nParticipants meeting the diagnostic criteria for distal radius fractures as outlined in both the Evidence-Based Guidelines for Diagnosis and Treatment of Adult Distal Radius Fractures (2024) (10) and the clinical practice guidelines (CPG) jointly issued by the American Academy of Orthopaedic Surgeons (AAOS) and the American Society for Surgery of the Hand (ASSH) (11), while also satisfying the following conditions, will be eligible for enrollment:\n\n1. Within 1 week post closed reduction and small splint immobilization treatment.\n2. Aged between 18 and 85 years (inclusive).\n3. Fracture caused by trauma.\n4. Acute fracture (≤2 weeks) or first-time fracture.\n5. No prior history of receiving Fu's subcutaneous needling therapy.\n6. Signed informed consent form obtained.\n\nExclusion Criteria:\n\n1. Pathological, open, or nonacute fractures (\\>2 weeks since injury).\n2. Patients with thrombocytopenia, bleeding tendency, or coagulation disorders (INR \\>1.5 or platelet count \\\u003C50×10⁹\u002FL).\n3. Cognitive impairment or psychiatric disorders affecting treatment compliance and follow-up.\n4. Local skin lesions, pregnancy, or lactation.\n5. History of syncope during Fu's subcutaneous needling therapy or intolerance to the procedure.\n6. Participation in other interventional clinical trials within the past 3 months.","85 Years",{"count":89,"type":21},84,[24],"The goal of this clinical trial is to evaluate the efficacy and safety of Fu's subcutaneous needling (FSN) therapy combined with rehabilitation exercises in promoting fracture healing after conservative treatment of distal radius fractures (DRFs) in adult patients (aged 18-85 years) with acute DRFs. The main questions it aims to answer are:\n\n* Does FSN therapy accelerate radiographic union compared to Sham FSN therapy?\n* Does FSN therapy improve functional outcomes (e.g., pain, swelling, joint mobility) and anatomical stability (e.g., volar tilt, radial height) in DRF patients?\n\nResearchers will compare the FSN therapy plus rehabilitation training group to the Sham FSN therapy plus rehabilitation training group to see if FSN provides superior clinical benefits in fracture healing and functional recovery.\n\nParticipants will:\n\n1. Receive either FSN or Sham FSN therapy (12 sessions over 8 weeks) alongside standardized rehabilitation exercises.\n2. Undergo periodic assessments (weeks 2, 4, 6, 8, 10, and 12) for radiographic union, pain (VAS), swelling, wrist mobility, and functional status (DASH questionnaire).\n3. Follow a phased rehabilitation protocol, including finger\u002Fshoulder exercises (weeks 1-3), gentle wrist movements (weeks 4-5), and resistance training (week 6 onward).",[93],"Distal Radius Fractures",[95,96,97],"Fu's subcutaneous needle therapy","distal radius fractures","conservative treatment","RECRUITING","2025-08-18",{"date":101,"type":40},"2025-08-19",{"date":103,"type":40},"2025-04-15",{"date":105,"type":21},"2027-05",{"name":46,"class":47},{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100598232","phase-1-efficacy-and-mechanism-of-fus-subcutaneous-needling-treatment-for-migraine-without-aura-100598232","NCT07068815","Efficacy and Mechanism of Fu's Subcutaneous Needling Treatment for Migraine Without Aura","Fu's Subcutaneous Needling Treatment for Migraine Without Aura: A Randomized Controlled Trial Protocol","Inclusion Criteria:\n\n1. Meeting the diagnostic criteria for migraine without aura (MwoA) according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) ;\n2. Aged 18-65 years;\n3. A history of migraine for at least 1 year;\n4. At least 2 migraine attacks per month;\n5. No prophylactic medications or other treatments for migraine within the past month;\n6. Visual Analog Scale (VAS) score \\> 3;\n7. Willing and capable of providing written informed consent.\n\nExclusion Criteria:\n\n1. Diagnosed with other primary headaches such as neuropathic headache, cluster headache, or tension-type headache;\n2. Comorbid secondary headaches or other neurological disorders (e.g., headache due to anxiety, depression, Parkinson's disease, or intracranial lesions);\n3. Uncontrolled or undiagnosed systemic diseases that may interfere with the study, including severe hepatic, renal, cardiovascular, or cerebrovascular diseases; poorly controlled or untreated hypertension (systolic blood pressure \\> 160 mmHg and\u002For diastolic blood pressure \\> 100 mmHg); poorly controlled or untreated diabetes mellitus; malnutrition; hyperthyroidism; or hepatic insufficiency;\n4. Comorbid uncontrolled psychiatric disorders;\n5. Pregnancy, lactation, or women in the preparation, menstrual, or menopausal phase;\n6. Use of prophylactic medications or other treatments for migraine within the past month;\n7. History of allergy to the trial medications or contraindications to flunarizine hydrochloride or ibuprofen;\n8. Skin lesions at the FSN operation site;\n9. Occupations involving driving, working at heights, or other high-risk activities;\n10. Refusal to undergo FSN therapy or oral flunarizine hydrochloride.",{"count":115,"type":21},60,[117],"PHASE1","This study aimed to compare the analgesic efficacy and quality-of-life improvement between FSN and flunarizine hydrochloride in patients with migraine without aura. The core research questions addressed were: Q1: Whether FSN demonstrates superior or at least equivalent therapeutic effects compared to the active control drug (flunarizine hydrochloride) in pain relief and quality-of-life enhancement for migraine without aura patients; Q2: To elucidate the mechanism of FSN in treating migraine without aura from a cerebral hemodynamic perspective. Participants will:1. Group allocation: A randomized design was employed, with 30 participants enrolled per group. 2. Interventions: Experimental group: Subjected to FSN monotherapy; Control group: Treated with oral flunarizine hydrochloride. 3. Treatment duration: All participants received a 4-week therapeutic intervention. 4. Outcome measures: The following parameters were systematically evaluated during treatment and follow-up: Visual Analog Scale (VAS) scores 、Migraine-Specific Quality of Life (MSQOL) scores、Near-infrared spectroscopy (NIRS) examinations.Researchers will compare FSN to flunarizine hydrochloride(a clinically established medication) to see if FSN exhibits superior or non-inferior efficacy to treat migraine without aura.",[120],"Migraine Without Aura",[122,123,124],"Fu's Subcutaneous Needling","migraine without aura","flunarizine hydrochloride","2025-07-15",{"date":127,"type":40},"2025-07-16",{"date":129,"type":21},"2025-09-01",{"date":131,"type":21},"2027-06-01",{"name":46,"class":47},""]